Market Will Be Unchanged by 48% Effectiveness of Flu Vaccine This Year

Market Will Be Unchanged by 48% Effectiveness of Flu Vaccine This Year

The CDC recently said this year's flu vaccine was 48% effective. Despite that being lower than half, that's a good number. And for the most part, good or bad effectiveness doesn't change the vaccine market. In this article, we indicate why.


Five Things to Know About the Vaccine Industry in 2016

Five Things to Know About the Vaccine Industry in 2016

A lot happened in vaccines this year, but five trends stay out. The vaccine market continued its growth and innovation in 2016. Merck, Sanofi Pasteur, Pfizer, Glaxo Smith Kline and CSL are among the top companies in the market. Segment growth, the growing obesity challenge and delivery systems were among the trends noted this year. The healthcare market research publisher has studied vaccine markets for a decade, and this year published its report Vaccines 2016.

  • by bcarlson@marketresearch.com
  • October 8 2014
  • vaccine


UK Tackles Flu With Children Before It Reaches Adults

UK Tackles Flu With Children Before It Reaches Adults

Two- to four-year-olds in the UK are for the second time being offered an egg-based nasal vaccine, and the UK will expand to older children. The intention is to prevent influenza (flu) in hopes of not just protecting children from getting flu, but also of stopping the disease spreading from them to their family, caregivers and the wider population. As we’ve indicated in our report on Biopharmaceutical and Vaccine production, http://www.kaloramainformation.com/Biopharmaceutical-Vaccine-Production...

  • by bcarlson@marketresearch.com
  • May 6 2014
  • vaccine
  • flu


Vaccine Revenues Near 24 Billion

Vaccine Revenues Near 24 Billion

In 2013, the world market for preventive vaccines totaled $23.9 billion, up from $22.8 billion in 2012 as sales in all segments expanded, according to our latest report. Among some the growth leaders was influenza vaccines, where greater awareness, new products and overstock recovery lead to 3.1 billion in revenues, up from 2.8 billion in 2012.

The influenza increase is significant according to Kalorama because there had been a large decrease in the influenza vaccine market in 2011. Vaccines s...